吉 林 省 輝 南 長 龍 生 化 藥 業 股 份 有 限 公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited Jilin Province Huinan Changlong Bio-pharmacy Company Limited (股份代號：8049) 第一季度業績報告2021 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小型公司提供一個上 市的市場。有意投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投 資決定。 由於GEM上市公司一般為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣的證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示概不會就本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 本報告乃遵照GEM證券上市規則（「GEM上市規則」）提供有關吉林省輝南長龍生 ...

Financial Performance - The total revenue for the year ended December 31, 2020, was approximately RMB 622,250,000, representing a decrease of 3.7% compared to RMB 645,885,000 in the previous year[16]. - Profit attributable to owners of the Company decreased to RMB 126,558,000 from RMB 144,726,000 last year[16]. - Basic earnings per share decreased to RMB 22.59 cents from RMB 25.83 cents last year[16]. - For the year ended December 31, 2020, the Group's revenue decreased to RMB 622,250,000 from approximately RMB 645,885,000, representing a decline of about 3.6%[38]. - Profit for the year attributable to owners of the Company decreased to RMB 126,558,000 from RMB 144,726,000, a decrease of approximately 12.6%[38]. - Basic earnings per share decreased to RMB 22.59 cents from RMB 25.83 cents, reflecting a decline of about 12.5%[38]. - The audited profit attributable to owners of the Company was approximately RMB 126,558,000, representing a decrease of 12.55% from RMB 144,726,000 in the previous year[99]. - Profit before income tax for 2020 was RMB 150,041,000, down from RMB 175,294,000 in 2019, reflecting a decline of 14.4%[173]. Operational Challenges - The COVID-19 outbreak significantly impacted the global economy, but the Company resumed work and production promptly to minimize the impact on production and sales[18]. - The Company faced increased production costs due to stricter environmental and resource constraints, as well as declining overall drug prices following the implementation of drug price control policies[19]. - The Company faced considerable operational pressure due to rising production costs and declining overall price levels of pharmaceutical products[37]. Strategic Initiatives - The Group emphasized the research and development of new drugs, increasing investment in technologically advanced new drugs with independent intellectual property rights[23]. - The Group's strategy includes exploring and adjusting business strategies and increasing investment in technology to pursue sustainable development[26]. - The Company plans to develop 16 new varieties of generic drugs through newly built workshops for research and production[98]. - The Group aims to achieve rapid growth and become a centennial enterprise by focusing on technological innovation and serving global health needs[33]. Financial Management - The expected annualized rate of return for wealth management products subscribed during the year was around 1.58%–3.8%, which was higher than comparable market bank deposit interest rates[40]. - As of December 31, 2020, the Group held Wealth Management Products totaling approximately RMB 60,417,000, a decrease from RMB 683,483,000 in 2019[91]. - The expected annualized return rate for the subscribed Wealth Management Products ranged from 1.20% to 3.80%[91]. - The unrealized gains on fair value change from the Wealth Management Products amounted to approximately RMB 417,000 as of December 31, 2020[92]. - The Group's investment in time deposits as of December 31, 2020, amounted to approximately RMB 805,020,000, compared to RMB Nil in 2019[91]. - The management has shifted investment strategy towards time deposits due to decreasing expected returns on Wealth Management Products[94]. - The Group established a Risk Management Committee to enhance the assessment and management of investments in Wealth Management Products and time deposits[94]. - The subscriptions of Wealth Management Products were aimed at maximizing the utilization of surplus cash while maintaining high liquidity and low risk[94]. - The Group did not experience any losses on the Wealth Management Products as of December 31, 2020[94]. - The Group will continue to seek opportunities to invest idle cash in appropriate Wealth Management Products[94]. Asset and Liability Management - Total assets increased to RMB 1,804,503,000 from RMB 1,671,477,000 in 2019[110]. - The total liabilities to total assets ratio was 25% in 2020, slightly down from 26% in 2019, with total liabilities amounting to RMB 459,021,000[114]. - The Group's gearing ratio was 0.02% in 2020, compared to 0.2% in 2019, indicating a significant reduction in leverage[114]. - The Group's total equity rose to RMB 1,345,482,000 in 2020, up from RMB 1,238,533,000 in 2019, marking an increase of about 8.6%[112]. - The total borrowings of the Group were RMB 400,000 as of December 31, 2020, significantly reduced from RMB 2,350,000 in 2019[112]. - The Group's current liabilities amounted to RMB 415,435,000 in 2020, compared to RMB 387,872,000 in 2019, indicating an increase of approximately 7.4%[112]. Employee and Community Engagement - The Group employed a total of 951 employees, with remuneration based on market conditions and individual performance[115]. - The Group has maintained compliance with all relevant laws and regulations, emphasizing its commitment to environmental and social standards[116]. - The Group encourages participation in environmental and social activities among employees, customers, and suppliers to benefit the community[116]. Future Outlook - The company has outlined a positive outlook for 2021, projecting a revenue growth of 10% to 12% based on current market trends and product demand[141]. - New product development includes the launch of two innovative drug formulations, which are expected to contribute an additional 200 million CNY in revenue in the upcoming fiscal year[141]. - The company is expanding its market presence, targeting an increase in distribution channels by 25% in 2021 to enhance accessibility of its products[141]. - A strategic acquisition of a smaller biotech firm is planned, which is anticipated to enhance the company's R&D capabilities and product pipeline[141]. - The company has invested 50 million CNY in new technology for production efficiency, aiming to reduce costs by 15% over the next two years[141]. - The R&D department has successfully filed for three new patents in 2020, focusing on advanced extraction methods that could improve product efficacy[141]. - The company has established a partnership with a leading university to foster innovation in drug development, which is expected to yield new products within the next 18 months[141]. - The management team has emphasized a commitment to sustainability, with plans to reduce carbon emissions by 30% by 2025 through improved operational practices[141].

吉 林 省 輝 南 長 龍 生 化 藥 業 股 份 有 限 公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited Jilin Province Huinan Changlong Bio-pharmacy Company Limited (股份代號：8049) 第三季度業績報告2020 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小型公司提供一個上 市的市場。有意投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投 資決定。 由於GEM上市公司一般為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣的證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就因本報告全部或部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本報告（吉林省輝南長龍生化藥業股份有限公司的董事（「董事」）願 ...

吉 林 省 輝 南 長 龍 生 化 藥 業 股 份 有 限 公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited Jilin Province Huinan Changlong Bio-pharmacy Company Limited (股份代號：8049) 中期報告2020 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小型公司提供一個上 市的市場。有意投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投 資決定。 由於GEM上市公司一般為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣的證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不會就因本報告全部或部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本報告（吉林省輝南長龍生化藥業股份有限公司的董事（「董事」）願共同及個 ...

吉林省輝南長龍生化藥業股份有限公司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited (於中華人民共和國註冊成立之股份有限公司) (a joint stock limited company incorporated in the People's Republic of China with limited liability) (股份代號 : 8049) (Stock Code : 8049) 型 圓两種字 Z20050062 | --- | --- | --- | |--------|--------------------------------------------------|-------------------| | | | | | 长龙 8 | | 国药准字H20100119 | | | 注射用盐酸头孢甲厉 | | | | Cefmenoxime Hydrochloride for Injection 每盒10狂 | | | | 凭医卿处方销售、购买和使用! | 百兽长年 (43) | 清 通 国药冶字H2008059 ...

吉 林 省 輝 南 長 龍 生 化 藥 業 股 份 有 限 公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited (於中華人民共和國註冊成立之股份有限公司) (股份代號：8049) 第一季度業績報告2020 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM的定位乃為相比其他在聯交所上市的公司可能帶有較高投資風險的中小型公司提供一個上 市的市場。有意投資者應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投 資決定。 由於GEM上市公司一般為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣的證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任 何聲明，並明確表示概不會就本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 本報告乃遵照GEM證券上市規則（「GEM上市規則」）提供有關吉林省輝南長龍生化藥業股份有限 公司及其附屬公司（「本集團」）之資料，吉林省輝南長龍生化藥業股 ...

吉林省輝南長龍生化藥業股份有限公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 第三季度業績報告2019 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他在本交易所上市的公司帶有較高投資風險的公司提供一 個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周 詳的考慮後方作出投資決定。GEM的較高風險及其它特色表示GEM較適合專業及其他 老練投資者。 由於GEM上市公司新興的性質所然，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不會就因本報告全部或部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告（吉林省輝南長龍生化藥業股份有限公司的董事（「董事」）願共同及個別對此負全 責）乃 遵 照GEM證 券 上 ...

吉林省輝南長龍生化藥業股份有限公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited (a joint stock limited company incorporated in the People's Republic of China with limited liability) (Stock Code: 8049) Interim Report 2019 吉林省輝南長龍生化藥業股份有限公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 中期業績報告2019 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其他在本交易所上市的公司帶有較高投資風險的公司提供一個上市的 市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出 投資決定。GEM的較高風險及其它特色表示GEM較適合專業及其他老練投資者。 由於GEM上市公司新興的性質所然，在 ...

吉林省輝南長龍生化藥業股份有限公 司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代號：8049） 第一季度業績報告2019 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM的定位，乃為相比起其他在本交易所上市的公司帶有較高投資風險的公司提供一 個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周 詳的考慮後方作出投資決定。GEM的較高風險及其他特色表示GEM較適合專業及其他 老練投資者。 由於GEM上市公司新興的性質使然，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不會就本報告全部或任何部分內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 本報告乃遵照GEM證券上市規則提供有關吉林省輝南長龍生化藥業股份有限公司及其 附 屬 公 司（「本 集 團」）之 資 料，吉 ...

CHANGLONGPAI 吉林省輝南長龍生化藥業股份有限公司 Jilin Province Huinan Changlong Bio-pharmacy Company Limited (於中華人民共和國註冊成立之殿份有限公司) (a joint stock limited company incorporated in the People's Republic of China with limited liability) (股份代號 : 8049) (Stock Code : 8049) 注射用盐酸头孢甲所 Celmenoxime Hydrochloride for injection 西昌长尾 ... , 62. NO.S.H1.02 | --- | --- | --- | |-------|-------|-------| | | | | | | | | | | | | | --- | --- | |---------------------------------|-------| | | | | | (13) | | a的准学Z20026288 复方活脑舒胶囊 | | | FuFangHuoNa ...